Cadila Pharmaceuticals has announced a slew of initiatives on the research and development front as part of its endeavour to become a global drug company in the next three years.
The company has initiated talks with a foreign drugs firm to jointly develop new molecules for tuberculosis and malaria. Discussions are at an advanced stage and the drug developed by the two could be owned jointly.
Cadila Pharma sees huge potential for contract research, and is also working closely with another overseas pharma firm to develop new drugs for diabetes.